eMediHub Home Facebook Bookmark This Page Chinese English Indonesia
 
 
EM: support@emedihub.com
MSN:
Skype:
Dr. Hsieh Wen-son , Medical Director and Consultant Medical Oncologist

Medical Group: International Cancer Specialists
Qualification: B.S., M.D, BS Neuroscience (Tulane), MD (Johns Hopkins), Internal Medicine (Duke), Medical Oncology (Johns Hopkins), Diplomate Internal Medicine and Medical Oncology ABIM (USA)
Specialty: Medical Oncology
Medical Group Address: 290 Orchard Road #15-01/02/03 Paragon, Tower Lobby 2
Singapore 238859
Operating Hours: Mondays to Fridays: 8.30am to 6.00pm Saturdays: 8.30am to 1.00pm Closed on Sundays & Public Holidays
Years of Practise: 17
Practice Locations: International Cancer Specialists

1. Cancer Treatment
(i) Treatment: chemotherapy, co-ordination of overall treatment plan (may include other clinical specialties), after-treatment care, palliative care.

(ii) Cancer Types: breast, colon/rectum, lung, gastrointestinal, gynaecological, urological, head & neck, hepatobiliary, musculoskeletal, neurological, haematological malignancies.

(iii) Cancer Support Programmes: symptom management, infective precautions, dietary counselling, emotional counselling.

(iv) Clinical Trials

2. Cancer Screening
Screening plays a crucial role in detecting cancer in its early stages. When cancer is detected early, prompt intervention and treatment can lead to improved clinical outcomes.

International Cancer Specialists and its allied services offer a comprehensive cancer detection service, using top-of-the-line health screening and diagnostic technology. Screening procedures range from blood tests to radiological imaging, such as ultrasound scans, CT (computed tomography) scans, MRI (magnetic resonance imaging) scans and PET (positron emission tomography) scans.

Raising public awareness to recognize early warning signals is helpful, although cancer can occur in individuals with no symptoms or signs. Currently, clinical evidence best supports screening the general population for breast cancer, cervical cancer and colorectal cancer. Although screening measures for other cancers exist, there is a worldwide effort ongoing to evaluate their clinical impact.

Training and Sub-Specialty Training
Intern in Internal Medicine 1994-1995 (Duke University)
Junior Assistant Resident in Internal Medicine 1995-1996 (Duke University)
Senior Assistant Resident in Internal Medicine 1996-1997 (Duke University)
Post-Doctoral Fellow in Oncology 1997-2001 (Johns Hopkins University)

Dr. Hsieh is a specialist in the treatment of various types of cancers and is active in developing novel cancer diagnostics and molecularly targeted anti-cancer treatments. In addition, he serves as the Medical Director of International Cancer Specialists. His vision for International Cancer Specialists is to provide patient-centered cutting edge cancer care that is affordable and compassionate.

Born in Taiwan, Dr. Hsieh grew up in the United States and was educated in the United States and the United Kingdom. He attended college at Tulane University in New Orleans, Louisiana, graduating summa cum laude with a degree in Neuroscience. He went on to study philosophy and psychology at Oxford University, England on a prestigious Rhodes Scholarship. He then completed his medical training at some of the top academic institutions in the World, including a medical degree from Johns Hopkins University School of Medicine, internship and residency in Internal Medicine at Duke University and a fellowship in medical oncology at Johns Hopkins. Dr. Hsieh is certified in Internal Medicine and Medical Oncology by the American Board of Internal Medicine.

After completion of his medical training, Dr. Hsieh was active in patient care, teaching, and research in his posts as Consultant in Medical Oncology, Johns Hopkins Singapore International Medical Center and Assistant Professor in Oncology, Johns Hopkins University School of Medicine.

Dr. Hsieh has been working in Singapore since 2001 and has been active in the treatment of patients and development of novel cancer therapies. With a research interest in molecularly targeted cancer therapies and immunotherapy, he has led a number of international studies involving centers in Singapore, Hong Kong, Korea, and the United States examining novel treatments for nasopharyngeal carcinoma. Dr. Hsieh has authored a number of scientific articles, abstracts, and book chapters and has lectured extensively at regional and international medical and scientific conferences. In addition, he has received a number of awards, including a Cure for Lymphoma Foundation fellowship and a Rhodes Scholarship.

Dr. Hsieh is able to converse in English, Mandarin and Bahasa Indonesia.

Adjunct Assistant Professor, John Hopkins University School of Medicine
Visiting Consultant, National University Hospital
Member, Association for the Advancement of Cancer Research

Leading International Studies Examining Novel Treatments for Nasopharyngeal Carcinoma
Clinical Activities Certification, Certified in Medical Oncology by American Board (2001)
Clinical Activities Certification, Certified in Internal Medicine by American Board (1998)
Clinical Activities Certification, License to Practice Medicine, State of Maryland (1997)
Clinical Activities Certification, USMLE (1996)
Cure for Lymphoma Foundation Fellowship (2000)
Phi Beta Kappa
Aaron Hartman Prize in Experimental Psychology
Marshall Scholarship Finalist
Rhodes Scholarship
Dean/s Scholarship Tulane University

Research Fields
Development of Molecularly targeted therapies in Early Phase Clinical Trials.

Characterization of anti-tumor immune responses in patients with EBV-associated malignancies.

Immunotherapy and EBV lytic induction therapy in EBV-associated tumors.

Research Experiences
1. Doperminergic and Nore-epinephrine Pathways in the Brainstem of Microtus microgaster. Tulane University, 1988. Supervisor, Arnold Gerall, Ph.D.

2. Aberrant Neural Pathways in the Nucleus accumbens of Patients with Untreated Schizoprenia. Neuropsychiatry Branch, National Institute of Mental Health, 1991. Supervisor: Janice Stevens, M.D. and Richard Wyatt, M.D.

3. Molecular Marker for Diagnosis and Staging for Prostate Carcinoma. Johns Hopkins University, 1992. Supervisor: Jonathan Simons, M.D.

4. AACR Workshop - Molecular Biology in Clinical Oncology. Aspen, Colorado, 1998.

5. AACR/ASCO Workshop - Methods in Clinical Cancer Research. Vail, Colorado, 2000.

6. AACR Clinical Trials Workshop - Singapore, 2007.

7. Clinical and Laboratory Research in EBV Associated Malignancies. Johns Hopkins University, 1998-2001. Supervisor, Richard Ambinder, M.D., Ph.D.
- Laboratory component: Ex vivo expansion and in vivo quantitation of antigen specific T cells.
- Authored 3 clinical protocols targeted therapies for EBV associated malignancies.
- Authored successful application for RAID funding from National Cancer Institute for US$ 250,000 for
development and manufacture of an EBV vaccine for prevention of post-transplant lymphoma in solid
organ transplant patients.
- Developed and supervised validation of a process for manufacture of an EBV vaccine for prevention
of post-transplant lymphoma in solid organ transplant patients. Authored successful Investigational
New Drug application to the FDA.

8. Currently principal investigator of 4 ongoing investigator initiated clinical trials.
- Valproic Acid for EBV Lytic Induction in localized NPC
- 5-azacytidine and SAHA for Epstein-Barr Virus lytic induction in metastatic NPC and Nasal NK-T cell
Lymphoma (Lead Investigator for Cooperative Group Trial in the Cancer Therapeutics Research
Group)
- Phase II study of Velcade for metastatic NPC (Lead Investigator for Cooperative Group Trial in the
Cancer Therapeutics Research Group)
- GM-CSF Secreting/LMP2/EBNA1 expressing allogeneic cell line vaccine for NPC

9. Co-investigator in additional 46 completed or ongoing clinical trials

Published Manuscripts
1. Hsieh, W.S. and Simons, J.W. Systemic Therapy of Prostate Cancer: New Concepts from Prostate Cancer Tumor Biology Cancer Treatment Reviews 19:229-260, 1993.

2. Lee, W.H, Morton, R.A, Epstein, J.I., Brooks, J.D., Campbell, P.A.,Bova, G.S.,Hsieh, W.S., Isaacs, W.B., and Nelson, W.G. Cytidine Methylation of Regulatory Sequences Near the Pi-Class Glutathione S-Transferase Gene Accompanies Human Prostatic Carcinogenesis. Proc. Natl.Acad. Sci. 91(24):11733-7, 1994.

3. Twillie, D.A., Eisenberger, M.A., Carducci, M.A., Hsieh, W.S., Kim, W.Y., and Simons, J.W. Interleukin-6: A Candidate Mediator of Human Prostate Cancer Morbidity. Urology. 45(3):542-9, 1995.

4. Hsieh, W.S., Szukala, S., Howell, D.N., and Conlon, P.J. Crescentic IgA Nephropathy and Acute Renal Failure in an HIV-positive patient with Enteric Salmonella Infection. Nephrology, Dialysis, and Transplantation. 11(11):2320-3, 1996.

5. Hsieh, W.S., Lemas, M.V., Ambinder, R.F. The Biology of Epstein-Barr Virus in Post-transplant Lymphoproliferative Disorders.Transplant Infectious Disease. 1:204-212,1999.

6. Hsieh, W.S. and Ambinder, R.F. Targeting Epstein-Barr virus in the Treatment of Nasopharyngeal Carcinoma. Cancer Reviews: Asia Pacific. 1(1):51-57, 2003.

7. Soo, RA, Putti, T, Tao, Q, Goh, BC, Lee, KH, Loh, T, Tan, L. Hsieh, WS. Cyclooxygenase-2 is overexpressed in Nasopharyngeal Carcinoma and correlates with Epidermal Growth Factor Receptor expression. Archives of Otolaryngology and Head and Neck Surgery. 131:147-152, 2005.

8. Ying JM, Srivastava G, Hsieh WS, Murray P, Gao, Z, Liao SK, Ambinder RF, Tao Q. Transcriptional Silencing of the Stress-responsive Growth Inhibitory Gene GADD45冘僴by Promoter Hypermethylation in Multiple Tumors. Clinical Cancer Research11 (18):6442-6449, 2005.

9. Loh, KS, Goh, BC, Lu, J., Hsieh, WS, Tan, L. Familial Nasopha